Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

Iannone, Florenzo; Semeraro, Angelo; Carlino, Giorgio; Santo, Leonardo; Bucci, Romano; Quarta, L.; Maruotti, Nicola; Zuccaro, C.; Marsico, A.; Falappone, Paola Chiara Francesca; Mazzotta, Daniela; Cantatore, Francesco Paolo; Muratore, Maurizio; Lapadula, Giovanni

doi:10.1007/s40261-019-00782-9

Cited by 10 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early-line prescription was also a predictive factor for CZP treatment retention in the multivariable analysis. This is discordant with a previously published study, in which SpA patients showed similar retention rates of CZP, regardless of the line of treatment 41 . It is important to notice that only a few patients in our study were treated with CZP, especially in first line.…”

Section: Discussionsupporting

confidence: 81%

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Larid,

Baudens,

Tiemdjo-Djimaffo

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The objectives of our study were to assess retention rate, safety, and predictive factors for retention of subcutaneous (SC) TNF inhibitors (TNFi) (adalimumab (ADA), etanercept (ETN), golimumab (GOL), and certolizumab pegol (CZP)) in axial spondyloarthritis (axSpA) depending on the line of treatment in real-life conditions. A multicentre retrospective observational study was conducted including 552 patients fulfilling the ASAS criteria for axSpA followed in the RIC-France register who began SC-TNFi between 01/01/13 and 08/31/2018 for a total of 824 prescriptions. Taking all lines of treatment into account, GOL had a significantly higher retention rate compared with ADA, ETN, and CZP with a mean retention length of 59 months. As first-line bDMARDs, GOL had a significantly higher retention rate compared with ADA and ETN. ETN had the best retention rate when prescribed as at least 3rd bDMARD. Taking all lines of treatment into account, female sex, peripheral disease, BASDAI at initiation, and line of treatment were predictive factors for treatment cessation. Primary inefficiency was the most frequent reason for treatment cessation. In conclusion, GOL showed the highest retention rate in axSpA. Male sex, absence of peripheral disease, and early line of prescription were associated with better SC-TNFi retention in axSpA.

show abstract

Section: Discussionsupporting

confidence: 81%

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Larid,

Baudens,

Tiemdjo-Djimaffo

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“… 16–18 In our study, we did not find an association with a response and a biologic-naïve status as other studies have reported. 17 Additionally, it is observed that having positive anti-CCP is associated with a greater probability of response at month 12; this finding is similar to that reported with abatacept. 19 However, this finding is debatable as other studies have linked high anti-CCP levels with decreased response to anti-TNF.…”

Section: Discussionsupporting

confidence: 73%

Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients

Santos-Moreno¹,

Martínez²,

Ibatá³

et al. 2021

BTT

View full text Add to dashboard Cite

Objective Although it is known that methotrexate (MTX) increases the effectiveness of biological drugs (mainly anti-TNFs) in patients with rheumatoid arthritis (RA), in real life, it is known that many patients using anti-TNFs are on monotherapy due to many causes. This article compares the effectiveness of certolizumab as monotherapy as combined with MTX or leflunomide (LFN) in RA patients with failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in a real-world setting. Methods A retrospective observational cohort study was conducted at a specialized centre for RA management in Colombia. Patients treated with certolizumab as monotherapy or in combination with MTX, LFN, or MTX+LFN, between 2011 and 2020 with a minimum 3-month follow-up were included. Demographics and RA clinical characteristics were recorded; effectiveness was assessed as the improvement in Disease Activity Score (DAS28) getting remission or low disease activity at 3, 6, and 12 months of treatment. Results A total of 181 patients were included, 24 received certolizumab as monotherapy, 62 certolizumab plus MTX, 47 certolizumab plus LFN and 48 certolizumab plus MTX+LFN. At 3 months of follow-up, 80% of the patients showed decreased disease activity, with no significant differences between groups; at 12 months of treatment, response in certolizumab monotherapy group was 94.4% compared to 81.8% in combination with MTX, 80.5% in combination with LFN and 51.4% in combination with MTX+LFN. Response at 3 months (OR 4.04; 95% CI 1.28–12.69) and positive anti-CCP (OR 3.83; 95% CI 1.11–13.21) were associated with 12-month response. Conclusion Certolizumab seems to be effective as monotherapy in the treatment of RA patients with failure to csDMARDs.

show abstract

“…In the past decades, national and regional registries were established to evaluate anti-TNF agents in the treatment of RA [ 10 ]. However, most evaluated the earliest agents, such as IFX and etanercept, and only a few published registries included data on the newer anti-TNFs such as adalimumab [ 11 , 12 ], certolizumab-pegol [ 13 , 14 ] and GLM [ 15 ]. BioTRAC was one of the longest running RA registries and included data on both old (IFX) and new (GLM) anti-TNF agents.…”

Section: Discussionmentioning

confidence: 99%

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

Rahman

Baer²,

Keystone

et al. 2020

BMC Rheumatol

View full text Add to dashboard Cite

Background Long-term clinical registries are essential tools to evaluate new therapies in a patient population that differs from those in randomized clinical trials. The objectives are to describe the profile of rheumatoid arthritis (RA) patients treated with anti-TNF agents in Canadian routine care. Methods RA patients eligible for treatment with Infliximab (IFX), golimumab (GLM) or intravenous golimumab (GLM-IV) as per their respective Canadian product monographs were enrolled into the BioTRAC registry between 2002 and 2017. Study visits occurred at baseline and every 6 months thereafter. Effectiveness was assessed by changes in disease activity. Safety was evaluated by the incidence of adverse events (AEs) and drug survival. Results Of the 890 IFX-, 530 GLM- and 157 GLM-IV-treated patients, the proportion of females ranged from 77.0–86.6%, the mean ages from 55.8–57.7 and the mean disease duration from 6.5–8.6 years. A significant decrease in baseline disease duration and disease activity parameters (DAS, TJC, SJC, HAQ, AM stiffness, MDGA, PtGA, CRP, ESR) was observed over time. Treatment with IFX, GLM- and GLM-IV significantly improved all disease parameters over time. The incidence of AEs was 105, 113 and 82.6 /100 PYs and the incidence of SAEs was 11.7, 11.2 and 4.68 /100 PYs for IFX, GLM- and GLM-IV-treated patients, respectively. Conclusion Differences in baseline characteristics between patients treated with an anti-TNFs over time shows the evolution of treatment modalities over time. All treatments significantly reduced disease activity and improved functionality in a similar fashion. The incidence of adverse events was consistent with the safety profiles of IFX and GLM. Trial registration ClinicalTrials.gov Identifier: NCT00741793 (Retrospectively registered on August 26, 2008).

show abstract

Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

Cited by 10 publications

References 21 publications

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

Certolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

Contact Info

Product

Resources

About